Clinical trials - Press Releases

Date	Title	Company
12-Dec-2019	Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene	Vertex Pharmaceuticals
12-Dec-2019	CarThera signs a strategic collaboration with Lantheus for its SonoCloud device microbubbles	CarThera
12-Dec-2019	Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform	Syndivia
12-Dec-2019	Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)	Sanofi
12-Dec-2019	Emergex Successfully Completes Preclinical Testing of its Lead ‘Set-Point’ Vaccine Candidate for Dengue Fever and Other Flaviviruses	Emergex Vaccines Holding Limited
12-Dec-2019	Darzalex®▼ (daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Ineligible for Transplant	the Janssen Pharmaceutical Companies of Johnson & Johnson
12-Dec-2019	Darzalex®▼ (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma	The Janssen Pharmaceutical Companies of Johnson & Johnson
12-Dec-2019	KITE, A GILEAD COMPANY, PRESENTS RESULTS FROM PIVOTAL ZUMA-2 TRIAL IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA	Kite, a Gilead Company
12-Dec-2019	PureTech Affiliate Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)	Vedanta Biosciences
12-Dec-2019	Freeline appoints Julia P Gregory to its Board of Directors	Freeline
12-Dec-2019	Forendo Pharma Signs Important License and Collaboration Deal with Leading Pharma Company	Forendo Pharma
12-Dec-2019	Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors	Transgene
12-Dec-2019	Clevegen downregulates a range of major immuno-oncology (IO) checkpoints in MATINS cancer patients Biomarker analysis could guide future combination therapies with Clevegen	Faron Pharmaceuticals Oy
11-Dec-2019	Dr Samareh Lajaunias, Director at Combioxin Speaking at SMi's 22nd Annual Superbugs & Superdrugs Conference	SMi Group
11-Dec-2019	Invite from Lynne Ensor chair for Pharma Microbiology East Coast Conference, April 2020, Boston	SMi Group
11-Dec-2019	Inceptua Appoints New CEO	Inceptua
10-Dec-2019	Peregrine Ventures Raises $115 Million for its Fourth Fund Bringing Total Managed Funds and Co-Invest Capital to $400 Million	Peregrine
10-Dec-2019	Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion	Sanofi
10-Dec-2019	Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak	Bavarian Nordic
10-Dec-2019	bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition	bluebird bio, Inc